NCT05682222View on ClinicalTrials.gov

Evaluation of the Immunopharmacology of EDP1815 and EDP2939

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

October 14, 2022

Study Completion Date

October 14, 2022

Conditions
KLH and Imiquimod Induced Skin Inflammation in Healthy Volunteers
Interventions
DRUG

EDP1815

EDP1815 is an essentially non-viable, non-replicating pharmaceutical preparation of a single strain of Prevotella histicola, a naturally occurring human commensal microbe.

DRUG

EDP2939

EDP2939 is a pharmaceutical preparation of extracellular vesicles.

DRUG

Placebo oral capsule

Placebo.

Trial Locations (1)

2333 CL

Centre for Human Drug Research, Leiden

Sponsors
All Listed Sponsors
lead

Evelo Biosciences, Inc.

INDUSTRY

NCT05682222 - Evaluation of the Immunopharmacology of EDP1815 and EDP2939 | Biotech Hunter | Biotech Hunter